WO2018169811A1 - Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant - Google Patents

Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant Download PDF

Info

Publication number
WO2018169811A1
WO2018169811A1 PCT/US2018/021897 US2018021897W WO2018169811A1 WO 2018169811 A1 WO2018169811 A1 WO 2018169811A1 US 2018021897 W US2018021897 W US 2018021897W WO 2018169811 A1 WO2018169811 A1 WO 2018169811A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
synthetic nanocarriers
sel
uricase
immunosuppressant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/021897
Other languages
English (en)
French (fr)
Inventor
Lloyd Johnston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cartesian Therapeutics Inc
Original Assignee
Selecta Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020197029716A priority Critical patent/KR102753928B1/ko
Priority to CA3055936A priority patent/CA3055936A1/en
Priority to KR1020257000660A priority patent/KR20250011715A/ko
Priority to EP18714906.7A priority patent/EP3592389B1/en
Priority to EP25159772.0A priority patent/EP4599848A3/en
Priority to AU2018236123A priority patent/AU2018236123B2/en
Priority to BR112019018748-0A priority patent/BR112019018748B1/pt
Priority to CN201880030393.7A priority patent/CN110612122A/zh
Priority to ES18714906T priority patent/ES3036482T3/es
Application filed by Selecta Biosciences Inc filed Critical Selecta Biosciences Inc
Priority to MX2019010757A priority patent/MX2019010757A/es
Priority to JP2019549532A priority patent/JP7523909B2/ja
Publication of WO2018169811A1 publication Critical patent/WO2018169811A1/en
Priority to IL26920019A priority patent/IL269200A/en
Anticipated expiration legal-status Critical
Priority to JP2024016220A priority patent/JP2024083324A/ja
Priority to AU2024204850A priority patent/AU2024204850A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase

Definitions

  • composition comprising synthetic nanocarriers comprising an immunosuppressant and the composition comprising an uricase.
  • composition(s) comprising an infusion reaction therapeutic is/are administered at least once prior to the composition comprising synthetic nanocarriers comprising an immunosuppressant and the composition comprising an uricase.
  • composition(s) comprising an infusion reaction is administered at least once prior to the composition comprising synthetic nanocarriers comprising an immunosuppressant and the composition comprising an uricase.
  • Subject means animals, including warm blooded mammals such as humans and 0 primates; avians; domestic household or farm animals such as cats, dogs, sheep, goats, cattle, horses and pigs; laboratory animals such as mice, rats and guinea pigs; fish; reptiles; zoo and wild animals; and the like.
  • the subject is human.
  • the subject is any one of the subjects provided herein, such as one that in is need thereof, such as in need of treatment with an uricase.
  • the synthetic nanocarriers comprise a polymer as provided herein.
  • Polymers may be natural or unnatural (synthetic) polymers.
  • Polymers may be homopolymers or copolymers comprising two or more monomers. In terms of sequence, copolymers may be random, block, or comprise a combination of random and block sequences.
  • polymers in accordance with the present invention are organic polymers.
  • the synthetic nanocarriers comprise polymer that is biodegradable. Therefore, in such embodiments, the polymers of the synthetic product
  • the polymers of a synthetic nanocarrier associate to form a polymeric matrix.
  • a wide variety of polymers and methods for forming polymeric matrices therefrom are known conventionally.
  • a synthetic nanocarrier comprising a hydrophobic polyester has a hydrophobic environment within the synthetic nanocarrier.
  • polymers may be modified with one or more moieties and/or functional groups.
  • moieties or functional groups can be used in accordance with the present invention.
  • polymers may be modified with polyethylene glycol (PEG), with a carbohydrate, and/or with acyclic polyacetals derived from
  • a portion of the nanocarriers is washed by transferring the nanocarrier suspension to a centrifuge tube and centrifuging at 75,600xg at 4 °C for 50 minutes, removing the supernatant, and re-suspended the pellet in DPBS containing 0.25% w/v PVA.
  • the wash procedure is repeated and the pellet is re-suspended in DPBS containing 0.25% w/v PVA to achieve a nanocarrier suspension having a nominal concentration of 10 mg/mL on a polymer basis.
  • the nanocarrier suspension is then filtered using a 0.22 ⁇ PES membrane syringe filter from MilliporeSigma (EMD Millipore, 290 Concord Rd. Billerica MA, product code SLGP033RB). The filtered nanocarrier suspension is stored at -20°C.
  • immunosuppressant provided herein can be 0.050 mg/kg, 0.055 mg/kg, 0.060 mg/kg, 0.065 mg/kg, 0.070 mg/kg, 0.075 mg/kg, 0.080 mg/kg, 0.085 mg/kg, 0.090 mg/kg, 0.095 mg/kg, 0.100 mg/kg, 0.105 mg/kg, 0.110 mg/kg, 0.115 mg/kg, 0.120 mg/kg, 0.125 mg/kg, 0.130 mg/kg, 0.135 mg/kg, 0.140 mg/kg, 0.145 mg/kg, 0.150 mg/kg, 0.155 mg/kg, 0.160 mg/kg, 0.165 mg/kg, 0.170 mg/kg, 0.175 mg/kg, 0.180 mg/kg, 0.185 mg/kg, 0.190 mg/kg, 0.195 mg/kg, 0.200 mg/kg, 0.205 mg/kg, 0.210 mg/kg, 0.215 mg/kg, 0.220 mg/kg, 0.225 mg/kg, 0.230 mg/kg, 0.235 mg/kg, 0.
  • the treatment with a combination of synthetic nanocarrier composition comprising immunosuppressant, such as rapamycin, with a composition comprising uricase, such as pegylated uricase can comprise three doses of the synthetic nanocarrier composition concomitantly with the uricase-comprising composition followed by two doses of uricase without the concomitant administration of a composition comprising an immunosuppressant, such as a synthetic nanocarrier composition comprising an immunosuppressant, with or without the concomitant administration of an additional therapeutic.
  • each dose may be administered every two to four weeks.
  • a method whereby any one of the subjects provided herein is concomitantly administered three doses of a synthetic nanocarrier composition with a uricase-comprising composition monthly for three months.
  • this method further comprises administering 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more monthly doses of a uricase-comprising composition alone or without the concomitant administration of immunosuppressant, such as a synthetic nanocarrier composition comprising an
  • the subject has a plasma or serum uric acid level of 5.0 mg/dL, 5.1 mg/dL, 5.2 mg/dL, 5.3 mg/dL, 5.4 mg/dL, 5.5 mg/dL, 5.6 mg/dL, 5.7 mg/dL, 5.8 mg/dL, 5.9 mg/dL, 6.0 mg/dL, 6.1 mg/dL, 6.2 mg/dL, 6.3 mg/dL, 6.4 mg/dL, 6.5 mg/dL, 6.6 mg/dL, 6.7 mg/dL, 6.8 mg/dL, 6.9 mg/dL, or 7.0 mg/dL.
  • Fig. 3 depicts average serum uric acid levels of the Phase la clinical trial's five cohorts tested at different measurement intervals (Day 7, 14, 21 and 30) during the course of the 30 day period following the single intravenous infusion of pegsiticase at the outset of the5 trial.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PCT/US2018/021897 2017-03-11 2018-03-11 Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant Ceased WO2018169811A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
ES18714906T ES3036482T3 (en) 2017-03-11 2018-03-11 Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
KR1020257000660A KR20250011715A (ko) 2017-03-11 2018-03-11 항염증제, 및 면역억제제를 포함하는 합성 나노담체를 사용한 조합 치료와 관련된 방법 및 조성물
EP18714906.7A EP3592389B1 (en) 2017-03-11 2018-03-11 Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
EP25159772.0A EP4599848A3 (en) 2017-03-11 2018-03-11 Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
AU2018236123A AU2018236123B2 (en) 2017-03-11 2018-03-11 Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
BR112019018748-0A BR112019018748B1 (pt) 2017-03-11 2018-03-11 Composições e seus usos no tratamento combinado com antiinflamatórios e nanocarreadores sintéticos compreendendo um imunossupressor
CN201880030393.7A CN110612122A (zh) 2017-03-11 2018-03-11 与用抗炎剂和包含免疫抑制剂之合成纳米载体进行的组合治疗相关的方法和组合物
KR1020197029716A KR102753928B1 (ko) 2017-03-11 2018-03-11 항염증제, 및 면역억제제를 포함하는 합성 나노담체를 사용한 조합 치료와 관련된 방법 및 조성물
MX2019010757A MX2019010757A (es) 2017-03-11 2018-03-11 Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor.
CA3055936A CA3055936A1 (en) 2017-03-11 2018-03-11 Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
JP2019549532A JP7523909B2 (ja) 2017-03-11 2018-03-11 抗炎症剤および免疫抑制剤を含む合成ナノキャリアによる組み合わせ処置に関連する方法および組成物
IL26920019A IL269200A (en) 2017-03-11 2019-09-09 Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
JP2024016220A JP2024083324A (ja) 2017-03-11 2024-02-06 抗炎症剤および免疫抑制剤を含む合成ナノキャリアによる組み合わせ処置に関連する方法および組成物
AU2024204850A AU2024204850A1 (en) 2017-03-11 2024-07-15 Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762470250P 2017-03-11 2017-03-11
US62/470,250 2017-03-11

Publications (1)

Publication Number Publication Date
WO2018169811A1 true WO2018169811A1 (en) 2018-09-20

Family

ID=61837835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/021897 Ceased WO2018169811A1 (en) 2017-03-11 2018-03-11 Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant

Country Status (12)

Country Link
US (4) US11426451B2 (https=)
EP (2) EP4599848A3 (https=)
JP (2) JP7523909B2 (https=)
KR (2) KR20250011715A (https=)
CN (1) CN110612122A (https=)
AU (2) AU2018236123B2 (https=)
CA (1) CA3055936A1 (https=)
ES (1) ES3036482T3 (https=)
HU (1) HUE072005T2 (https=)
IL (1) IL269200A (https=)
MX (1) MX2019010757A (https=)
WO (1) WO2018169811A1 (https=)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210021882A (ko) * 2019-08-19 2021-03-02 연세대학교 산학협력단 통풍 치료용 약학적 조성물 및 통풍 치료용 키트
WO2021081062A1 (en) * 2019-10-21 2021-04-29 Selecta Biosciences, Inc. Methods and compositions for treating liver diseases and disorders
WO2021092354A1 (en) * 2019-11-08 2021-05-14 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
US11235057B2 (en) 2011-04-29 2022-02-01 Selecta Biosciences, Inc. Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses
US11298342B2 (en) 2013-05-03 2022-04-12 Selecta Biosciences, Inc. Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity
US20220133864A1 (en) * 2020-11-04 2022-05-05 Selecta Biosciences, Inc. Methods and compositions for reducing immune responses against immunoglobulin proteases
US11426451B2 (en) 2017-03-11 2022-08-30 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with antiinflammatories and synthetic nanocarriers comprising an immunosuppressant
US11633422B2 (en) 2014-09-07 2023-04-25 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector immune responses
US12553041B2 (en) 2019-06-04 2026-02-17 Cartesian Therapeutics Inc. Formulations and doses of pegylated uricase

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE052976T2 (hu) 2005-04-11 2021-06-28 Horizon Pharma Rheumatology Llc Urát-oxidáz variáns formái és azok alkalmazása
HUP1200205A3 (en) 2009-06-25 2012-09-28 Savient Pharmaceuticals Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
CN110234340A (zh) 2016-11-11 2019-09-13 好利恩风湿病制药有限责任公司 泼尼松和尿酸酶分子的组合疗法及其用途
JP2020530282A (ja) 2017-07-07 2020-10-22 アレナ ファーマシューティカルズ， インコーポレイテッド 組換えウリカーゼ酵素
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
EP4021482A4 (en) * 2019-08-30 2023-04-19 Horizon Therapeutics Ireland Dac PEGLOTICASE FOR THE TREATMENT OF GOUT IN KIDNEY TRANSPLANT RECIPIENT
MX2023001740A (es) * 2020-08-10 2023-04-05 Horizon Therapeutics Usa Inc Metodos de tratamiento de la gota.
CN120152732A (zh) * 2022-10-24 2025-06-13 西湖生物医药科技(上海)有限公司 诱导特异性免疫耐受的组合
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Citations (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4806621A (en) 1986-01-21 1989-02-21 Massachusetts Institute Of Technology Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
US4946929A (en) 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US5010167A (en) 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
US5019379A (en) 1987-07-31 1991-05-28 Massachusetts Institute Of Technology Unsaturated polyanhydrides
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
US5514378A (en) 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5578325A (en) 1993-07-23 1996-11-26 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5700674A (en) 1995-08-24 1997-12-23 Kikkoman Corporation Mutant uricase, a mutant uricase gene, a novel recombinant DNA, and a process for producing mutant uricase
WO1998002441A2 (en) 1996-07-12 1998-01-22 Ariad Pharmaceuticals, Inc. Non immunosuppressive antifungal rapalogs
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US5736372A (en) 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
US5770417A (en) 1986-11-20 1998-06-23 Massachusetts Institute Of Technology Children's Medical Center Corporation Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo
US5804178A (en) 1986-11-20 1998-09-08 Massachusetts Institute Of Technology Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue
US5837752A (en) 1997-07-17 1998-11-17 Massachusetts Institute Of Technology Semi-interpenetrating polymer networks
US5902599A (en) 1996-02-20 1999-05-11 Massachusetts Institute Of Technology Biodegradable polymer networks for use in orthopedic and dental applications
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US6095148A (en) 1995-11-03 2000-08-01 Children's Medical Center Corporation Neuronal stimulation using electrically conducting polymers
US6123727A (en) 1995-05-01 2000-09-26 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
US6506577B1 (en) 1998-03-19 2003-01-14 The Regents Of The University Of California Synthesis and crosslinking of catechol containing copolypeptides
US6632671B2 (en) 2000-02-28 2003-10-14 Genesegues, Inc. Nanoparticle encapsulation system and method
US6632922B1 (en) 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6818732B2 (en) 2001-08-30 2004-11-16 The Regents Of The University Of California Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
US6913915B2 (en) 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US20060002852A1 (en) 2004-07-01 2006-01-05 Yale University Targeted and high density drug loaded polymeric materials
US20080145441A1 (en) 2000-10-16 2008-06-19 Midatech Limited Nanoparticles
US20090028910A1 (en) 2003-12-19 2009-01-29 University Of North Carolina At Chapel Hill Methods for Fabrication Isolated Micro-and Nano-Structures Using Soft or Imprint Lithography
WO2009051837A2 (en) 2007-10-12 2009-04-23 Massachusetts Institute Of Technology Vaccine nanotechnology
US8455510B2 (en) 2008-09-18 2013-06-04 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Rapamycin carbonic ester analogues, pharmaceutical compositions, preparations and uses thereof
WO2014179771A1 (en) * 2013-05-03 2014-11-06 Selecta Biosciences, Inc. Dosing combinations for reducing undesired humoral immune responses
US20160128987A1 (en) 2014-11-05 2016-05-12 Selecta Biosciences, Inc. Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state

Family Cites Families (254)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01502909A (ja) 1987-02-24 1989-10-05 ゾーマ・コーポレーション 免疫毒素による人間の治療における免疫抑制
US5912017A (en) 1987-05-01 1999-06-15 Massachusetts Institute Of Technology Multiwall polymeric microspheres
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5268455A (en) 1989-05-25 1993-12-07 Genentech, Inc. Process for making biologically active polypeptides based on transforming growth factor-βsequences
US5843452A (en) 1992-11-09 1998-12-01 Pharmagenesis, Inc. Immunotherapy composition and method
US5679347A (en) 1992-12-10 1997-10-21 Brigham And Women's Hospital Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods
EP0678034B1 (en) 1993-01-11 1999-05-26 Dana Farber Cancer Institute Inducing cytotoxic t lymphocyte responses
WO1995003035A1 (en) 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Polymerized liposomes with enhanced stability for oral delivery
TW249754B (https=) 1993-10-26 1995-06-21 Alpha I Biomedicals Inc
ATE196297T1 (de) 1994-05-18 2000-09-15 Synthetic Peptides Inc Heterodimere trägerzusammensetzung von immunogenen polypeptiden und verfahren zu deren verwendung
US5814617A (en) 1994-10-07 1998-09-29 The United States Of America As Represented By The Secretary Of The Navy Protective 17 KDA malaria hepatic and erythrocytic stage immunogen and gene
WO1996012406A1 (en) 1994-10-19 1996-05-02 Genetic Therapy, Inc. Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
EP0805678B1 (en) 1995-01-05 2003-10-29 THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN Surface-modified nanoparticles and method of making and using same
US6251957B1 (en) 1995-02-24 2001-06-26 Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
WO1998010056A1 (en) 1996-09-03 1998-03-12 Health Research Inc. Treatment of antigen presenting cells to modulate antigen presenting cell function
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
DK1017721T3 (da) 1997-09-16 2009-04-20 Univ Oregon Health & Science Rekombinante MHC molekyler, der kan anvendes til manipulation af antigenspecifikke T-celler
JP3790099B2 (ja) 1997-10-30 2006-06-28 シー・ビー・エフ・レティ・エス・エー 天然アレルゲンの寛容原性断片
US6018817A (en) 1997-12-03 2000-01-25 International Business Machines Corporation Error correcting code retrofit method and apparatus for multiple memory configurations
US6197229B1 (en) 1997-12-12 2001-03-06 Massachusetts Institute Of Technology Method for high supercoiled DNA content microspheres
JP2001526900A (ja) 1997-12-23 2001-12-25 イントロヘーネ ベスローテン フェンノートシャップ 標的細胞の染色体ｄｎａへの外来遺伝子情報の組み込みに有用な、アデノ随伴ウイルスおよびアデノウイルスのキメラ組換えウイルス
GB2348808B (en) 1998-01-09 2003-03-19 Circassia Ltd Methods and compositions for desensitisation
FR2775435B1 (fr) 1998-02-27 2000-05-26 Bioalliance Pharma Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
SE9801288D0 (sv) 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
US6436392B1 (en) 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
PL202799B1 (pl) 1998-08-06 2009-07-31 Mountain View Pharmaceuticals Sposób izolowania urykazy w postaci tetramerycznej oraz wyizolowana tetrameryczna urykaza
IL141868A0 (en) 1998-10-05 2002-03-10 M & E Biotech As Novel methods for therapeutic vaccination
US6306640B1 (en) 1998-10-05 2001-10-23 Genzyme Corporation Melanoma antigenic peptides
PT1783222E (pt) 1998-10-23 2012-07-26 Kirin Amgen Inc Péptidos diméricos de trombopoietina que simulam a ligação ao receptor mpl e têm actividade trombopoiética
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
DE69933044T3 (de) 1998-11-27 2016-11-24 Ucb Pharma, S.A. Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
US6153217A (en) 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
US6800296B1 (en) 1999-05-19 2004-10-05 Massachusetts Institute Of Technology Modification of surfaces using biological recognition events
WO2000074688A1 (en) 1999-06-08 2000-12-14 The Children's Hospital Of Philadelphia Methods for preventing formation of inhibitory antibodies in the setting of gene therapy
DE19951970A1 (de) 1999-10-28 2001-05-03 Bionetworks Gmbh Arzneimittel für die Toleranzinduktion
WO2001068133A1 (en) 2000-03-14 2001-09-20 Genetics Institute, Inc. Use of rapamycin and agents that inhibit b7 activity in immunomodulation
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
AU2001265187A1 (en) 2000-05-30 2001-12-11 Baylor College Of Medicine Chimeric viral vectors for gene therapy
NZ522840A (en) 2000-06-01 2004-12-24 Univ North Carolina A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
WO2001097829A2 (en) 2000-06-19 2001-12-27 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20020014242A1 (en) 2000-07-31 2002-02-07 Abraham Scaria Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
MY138883A (en) 2000-08-29 2009-08-28 Government Of Malaysia As Represented By The Ministry Of Science Tehnology And Innovation Malaysia Use of asiatic acid for treatment of cencer
CA2319928A1 (en) 2000-09-18 2002-03-18 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatments
WO2002088304A2 (en) 2001-04-11 2002-11-07 Trustees Of The University Of Pennsylvania Compositions and methods for suppressing immune responses
CN1294268C (zh) 2001-09-03 2007-01-10 上海三维生物技术有限公司 可在肿瘤细胞内特异性复制并扩散的重组腺病毒载体
US7141648B2 (en) 2001-10-19 2006-11-28 Isotechnika Inc. Synthesis of cyclosporin analogs
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
GB0207440D0 (en) 2002-03-28 2002-05-08 Ppl Therapeutics Scotland Ltd Tolerogenic antigen-presenting cells
US20040038303A1 (en) 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
US7485314B2 (en) 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
CA2486621A1 (en) 2002-05-22 2003-12-04 The Cleveland Clinic Foundation Induction and maintenance of tolerance to composite tissue allografts
AU2003237416A1 (en) 2002-06-04 2003-12-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Novel tolerogenic dendritic cells and therapeutic uses therefor
CA2494508A1 (en) 2002-07-03 2004-01-15 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
AU2003292137A1 (en) 2002-11-29 2004-06-23 Maria Grazia Roncarolo Rapamycin and il-10 for the treatment of immune diseases
WO2004071493A1 (en) 2003-02-17 2004-08-26 Peter Burkhard Peptidic nanoparticles as drug delivery and antigen display systems
WO2004075861A2 (en) 2003-02-26 2004-09-10 Children's Hospital, Inc. Recombinant adeno-associated virus production
CA2518371A1 (en) 2003-03-14 2004-09-30 Wyeth Antibodies against human il-21 receptor and uses therefor
EP1605972A2 (en) 2003-03-26 2005-12-21 Cytos Biotechnology AG Hiv-peptide-carrier-conjugates
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
EP1636270B1 (en) 2003-06-16 2016-07-20 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
US20060251711A1 (en) 2003-08-28 2006-11-09 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating diseases of the respiratory tract of a mammal
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US20080160089A1 (en) 2003-10-14 2008-07-03 Medivas, Llc Vaccine delivery compositions and methods of use
AU2004311630A1 (en) 2003-12-02 2005-07-21 Cytimmune Sciences, Inc. Methods and compositions for the production of monoclonal antibodies
JP5080241B2 (ja) 2004-04-08 2012-11-21 メルク セローノ ソシエテ アノニム Ｊｎｋ阻害剤およびスクロスポリンを含んでなる組成物
AU2005250170A1 (en) 2004-06-01 2005-12-15 Genimmune N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
US20080206270A1 (en) 2004-07-08 2008-08-28 Minev Boris R Enhancing Class I Antigen Presentation With Synthetic Sequences
FR2874384B1 (fr) 2004-08-17 2010-07-30 Genethon Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables
CN101432019A (zh) 2004-10-05 2009-05-13 泰勒公司 用抗IgE抗体治疗和预防接受替代治疗的患者体内的超敏反应和/或过敏症
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
CA2590675A1 (en) 2004-12-15 2006-06-22 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
CN101094659A (zh) 2004-12-31 2007-12-26 伊休蒂卡有限公司 纳米微粒组合物及其合成方法
GB0504206D0 (en) 2005-03-01 2005-04-06 Glaxo Group Ltd Combination therapy
AU2006222409A1 (en) 2005-03-08 2006-09-14 Lifecycle Pharma A/S Pharmaceutical compositions comprising sirolimus and/or an analogue thereof
US20060210638A1 (en) 2005-03-17 2006-09-21 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
EP1871343A2 (en) 2005-04-12 2008-01-02 Wisconsin Alumni Research Foundation Micelle composition of polymer and passenger drug
WO2006122223A2 (en) 2005-05-10 2006-11-16 Emory University Strategies for delivery of active agents using micelles and particles
TW200711649A (en) 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
MX2007016039A (es) 2005-06-17 2008-10-27 Univ North Carolina Metodos, sistemas y materiales de fabricacion de nanoparticulas.
EP1932538A4 (en) 2005-08-25 2009-10-21 Taiho Pharmaceutical Co Ltd BIODEGRADABLE NANOTEHICLES WITH IMMOBILIZED OR CAPACITATED T-CELL-RECOGNIZABLE EPITOPEPEPID
CN1979166A (zh) 2005-11-30 2007-06-13 北京有色金属研究总院 一种制备免疫检测用纳米胶体金的工艺方法及其反应装置
EP2345412A1 (en) 2005-12-02 2011-07-20 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs for treating immune disorders
US20070128289A1 (en) 2005-12-07 2007-06-07 Zhao Jonathon Z Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases
WO2007067683A2 (en) 2005-12-08 2007-06-14 University Of Louisville Research Foundation, Inc. Methods and compositions for expanding t regulatory cells
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
US20100028450A1 (en) 2006-01-25 2010-02-04 The Board Of Trustees Of The University Of Illinoi S Tolerogenic biodegradable artificial antigen presenting system
US20070190032A1 (en) 2006-02-13 2007-08-16 Oncolytics Biotech Inc. Use of Local Immune Suppression to Enhance Oncolytic Viral Therapy
US8021689B2 (en) 2006-02-21 2011-09-20 Ecole Polytechnique Federale de Lausanne (“EPFL”) Nanoparticles for immunotherapy
US8568487B2 (en) 2006-02-27 2013-10-29 Biomet Manufacturing, Llc Patient-specific hip joint devices
BRPI0709340A2 (pt) 2006-03-27 2013-04-16 Globeimmune, Inc. mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma
CA2650607A1 (en) 2006-04-28 2007-11-08 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of cardiovascular disease
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
US20110052697A1 (en) 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
EP1880729A1 (en) 2006-07-20 2008-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of soluble CD160 to suppress immunity
ES2526548T3 (es) 2006-08-18 2015-01-13 Argos Therapeutics, Inc. Uso de CD83 en terapias de combinación
WO2008036374A2 (en) 2006-09-21 2008-03-27 Medistem Laboratories, Inc. Allogeneic stem cell transplants in non-conditioned recipients
WO2008073558A2 (en) 2006-10-05 2008-06-19 The Johns Hopkins University Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles
CN101646418B (zh) 2006-10-12 2013-07-17 昆士兰大学 调节免疫应答的组合物和方法
JP2010505883A (ja) 2006-10-12 2010-02-25 ザ ユニバーシティー オブ クイーンズランド 免疫応答を調節するための組成物および方法
US20100112077A1 (en) 2006-11-06 2010-05-06 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
US20100172994A1 (en) 2006-11-22 2010-07-08 University Of Florida Research Foundation, Inc. Nanoparticles for Protection of Cells from Oxidative Stress
WO2008069942A2 (en) 2006-12-05 2008-06-12 Biogen Idec Ma Inc. Novel methods of enhancing delivery of a gene therapy vector using steroids
CN101646781B (zh) 2006-12-29 2016-06-22 科罗拉多大学董事会 自身免疫病的诊断和治疗靶标及其用途
JP5357782B2 (ja) 2007-02-21 2013-12-04 バクシネックス インコーポレーティッド 抗原負荷ＣＤ１ｄ分子によるＮＫＴ細胞活性の調節
KR20080078204A (ko) 2007-02-22 2008-08-27 크레아젠 주식회사 면역억제능이 증가된 간엽줄기세포-매개 자가유래수지상세포
WO2008109163A1 (en) 2007-03-07 2008-09-12 Abraxis Bioscience, Llc. Nanoparticle comprising rapamycin and albumin as anticancer agent
AU2008222678B2 (en) 2007-03-07 2013-01-17 The General Hospital Corporation Compositions and methods for the prevention and treatment of autoimmune conditions
CN101730526A (zh) 2007-03-07 2010-06-09 阿布拉科斯生物科学有限公司 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒
EP2079456B1 (en) 2007-04-04 2012-12-05 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
WO2008124632A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
CA2683063A1 (en) 2007-04-09 2008-10-16 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
SE531313C2 (sv) 2007-05-25 2009-02-17 Totalfoersvarets Forskningsins Piezokrom komposit
US20080311140A1 (en) 2007-05-29 2008-12-18 Baylor College Of Medicine Antigen specific immunosuppression by dendritic cell therapy
WO2008150868A1 (en) 2007-05-29 2008-12-11 The Board Of Trustees Of The University Of Illinois Methods for inducing therapeutic t cells for immune diseases
CN101765607B (zh) 2007-05-31 2015-09-09 莱顿教学医院 侵润宫颈恶性肿瘤的t细胞所靶向的用于疫苗的hpv表位
WO2008148761A1 (en) 2007-06-05 2008-12-11 Novartis Ag Induction of tolerogenic phenotype in mature dendritic cells
US20090004259A1 (en) 2007-06-14 2009-01-01 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) Methods of preparing a therapeutic formulation comprising galectin-induced tolerogenic dendritic cells
CN101809002B (zh) 2007-07-09 2013-03-27 阿斯利康(瑞典)有限公司 用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
MX2010001779A (es) 2007-08-15 2010-07-06 Circassia Ltd Peptidos para vacunas.
US20090104114A1 (en) 2007-09-21 2009-04-23 Cytimmune Sciences, Inc. Nanotherapeutic Colloidal Metal Compositions and Methods
WO2009062502A1 (en) 2007-11-13 2009-05-22 Dandrit Biotech A/S Method for generating tolerogenic dendritic cells employing decreased temperature
US20090142318A1 (en) 2007-11-30 2009-06-04 Therakos, Inc. METHOD TO EXPAND nTREG CELLS USING p70 S6 KINASE ANTAGONIST
WO2009088786A1 (en) 2007-12-31 2009-07-16 Nanocor Therapeutics, Inc. Rna interference for the treatment of heart failure
WO2009100394A2 (en) 2008-02-08 2009-08-13 Terumo Kabushiki Kaisha Device for local intraluminal transport of a biologically and physiologically active agent
EP2262489A2 (en) 2008-02-28 2010-12-22 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Hollow nanoparticles and uses thereof
CA2722184A1 (en) 2008-04-25 2009-10-29 Duke University Regulatory b cells and their uses
US8815817B2 (en) 2008-05-15 2014-08-26 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
JP5549014B2 (ja) 2008-05-27 2014-07-16 国立大学法人名古屋大学 免疫調節剤及びその利用
US20090297621A1 (en) 2008-06-03 2009-12-03 Abbott Cardiovascular Systems Inc. Microparticles For The Treatment Of Disease
JP2012501965A (ja) 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
US20120034155A1 (en) 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
WO2010018384A1 (en) 2008-08-15 2010-02-18 Circassia Limited T-cell antigen peptide from allergen for stimulation of il-10 production
US8323696B2 (en) 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
WO2010027471A2 (en) 2008-09-04 2010-03-11 The General Hospital Corporation Hydrogels for vocal cord and soft tissue augmentation and repair
US8889124B2 (en) 2008-09-25 2014-11-18 The Board Of Trustees Of The Leland Stanford Junior University Tolerogenic populations of dendritic cells
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
JP5552630B2 (ja) 2008-10-24 2014-07-16 学校法人 聖マリアンナ医科大学 Ｈｔｌｖ−ｉ関連脊髄症を治療または予防するための医薬、およびｈｔｌｖ−ｉ関連脊髄症の患者に対する抗体療法の効果を試験する方法
WO2010047839A1 (en) 2008-10-25 2010-04-29 Aura Biosciences Modified plant virus particles and uses therefor
WO2010056143A1 (en) 2008-11-13 2010-05-20 Instituto De Medicina Molecular The use of adjuvant to facilitate the induction of immune tolerance
US20100216804A1 (en) 2008-12-15 2010-08-26 Zale Stephen E Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
WO2010085509A1 (en) 2009-01-20 2010-07-29 Northwestern University Compositions and methods for induction of antigen-specific tolerance
EP2620447B1 (en) 2009-02-04 2015-09-09 Universität Leipzig Vector(s) containing an inducible gene encoding a CDK4/CDK6 inhibitor useful for treating neurodegenerative disorders
HRP20150317T1 (hr) 2009-02-05 2015-04-24 Circassia Limited Peptidi trave za cjepivo
KR20100099849A (ko) 2009-03-04 2010-09-15 동국대학교 산학협력단 면역억제제와 트랜스글루타미나제 2의 억제제를 함유한 아토피 피부염 치료용 조성물
US8679837B2 (en) 2009-04-02 2014-03-25 University Of Florida Research Foundation, Inc. Inducible system for highly efficient production of recombinant Adeno-associated virus (rAAV) vectors
GB0906159D0 (en) 2009-04-09 2009-05-20 Summit Corp Plc Drug combination for the treatment of proteostatic diseases
KR20120022984A (ko) 2009-04-21 2012-03-12 셀렉타 바이오사이언시즈, 인크. Ｔｈ１ 편향 반응을 제공하는 면역나노치료법
US20100273220A1 (en) 2009-04-22 2010-10-28 Massachusetts Institute Of Technology Innate immune suppression enables repeated delivery of long rna molecules
EA024697B1 (ru) 2009-04-27 2016-10-31 Иммурон Лимитед Применение композиции, содержащей обогащенный анти-lps-антителами иммуноглобулиновый препарат, для лечения заболеваний печени
CA2762653A1 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
HUP1200205A3 (en) 2009-06-25 2012-09-28 Savient Pharmaceuticals Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy
CN107617110A (zh) 2009-08-26 2018-01-23 西莱克塔生物科技公司 诱导t细胞辅助的组合物
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP2305277A1 (en) 2009-09-18 2011-04-06 Forskarpatent I Syd AB Use of tolerogenic dendritic cells in treatment and prevention of atherosclerosis
CN101703781A (zh) 2009-10-28 2010-05-12 陕西北美基因股份有限公司 一种免疫抑制剂的磁性载药方法
KR101267813B1 (ko) 2009-12-30 2013-06-04 주식회사 삼양바이오팜 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물
WO2011085231A2 (en) 2010-01-08 2011-07-14 Selecta Biosciences, Inc. Synthetic virus-like particles conjugated to human papillomavirus capsid peptides for use as vaccines
US9228171B2 (en) 2010-02-05 2016-01-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulatory B cells (tBREGS) and their use
JP2013521002A (ja) 2010-03-05 2013-06-10 プレジデント アンド フェロウズ オブ ハーバード カレッジ 誘導樹状細胞組成物及びその使用
US20110272836A1 (en) 2010-04-12 2011-11-10 Selecta Biosciences, Inc. Eccentric vessels
US20110262491A1 (en) 2010-04-12 2011-10-27 Selecta Biosciences, Inc. Emulsions and methods of making nanocarriers
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
KR20130065662A (ko) 2010-05-07 2013-06-19 조마 테크놀로지 리미티드 ⅠＬ-1β 관련 병태의 치료 방법
AU2011258165B2 (en) 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
WO2011156119A1 (en) 2010-06-07 2011-12-15 Abraxis Bioscience, Llc Combination therapy methods for treating proliferative diseases
EP2600878A4 (en) 2010-08-04 2014-06-11 Univ Duke REGULATORY B-CELLS AND ITS USES
WO2012021512A2 (en) 2010-08-10 2012-02-16 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US20120058153A1 (en) 2010-08-20 2012-03-08 Selecta Biosciences, Inc. Synthetic nanocarrier vaccines comprising proteins obtained or derived from human influenza a virus hemagglutinin
BR112013004288A2 (pt) 2010-08-23 2016-05-31 Selecta Biosciences Inc formas galênicas de múltiplos epítopos direcionados para indução de uma resposta imunológica a antigênios.
CA2810842C (en) 2010-09-09 2018-06-26 Micell Technologies, Inc. Macrolide dosage forms
JP2013540162A (ja) 2010-10-22 2013-10-31 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 抗原特異的な寛容を誘導する微粒子およびその使用
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
WO2012092552A1 (en) 2010-12-30 2012-07-05 Selecta Biosciences, Inc. Synthetic nanocarriers with reactive groups that release biologically active agents
EP2672977A1 (en) 2011-02-08 2013-12-18 The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System Antisense oligonucleotides
ES2685611T3 (es) 2011-02-14 2018-10-10 The Children's Hospital Of Philadelphia Vector VAA8 mejorado con una actividad funcional aumentada y métodos de utilización del mismo
US8654487B2 (en) 2011-03-11 2014-02-18 Siemens Industry, Inc. Methods, systems, and apparatus and for detecting parallel electrical arc faults
CA2830948A1 (en) 2011-03-25 2012-10-04 Selecta Biosciences, Inc. Osmotic mediated release synthetic nanocarriers
WO2012145509A2 (en) 2011-04-19 2012-10-26 The Research Foundation Of State University Of New York Adeno-associated-virus rep sequences, vectors, and viruses
EP2699688A1 (en) 2011-04-20 2014-02-26 The Trustees Of The University Of Pennsylvania Regimens and compositions for aav-mediated passive immunization of airborne pathogens
KR20140041505A (ko) 2011-04-29 2014-04-04 셀렉타 바이오사이언시즈, 인크. 조절 b 세포 유도를 위한 관용원성 합성 나노운반체
CN110124039A (zh) 2011-05-16 2019-08-16 建新公司 使用甲氨蝶呤诱导免疫耐受性
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
US20130058901A1 (en) 2011-09-06 2013-03-07 Selecta Biosciences, Inc. Transplantable graft-specific induced tolerogenic dendritic cells and methods of use
EP2753362A4 (en) 2011-09-08 2015-04-15 Univ Florida MATERIALS AND METHOD FOR MODULATING IMMUNE SYSTEM REACTIONS
US8865487B2 (en) 2011-09-20 2014-10-21 General Electric Company Large area hermetic encapsulation of an optoelectronic device using vacuum lamination
WO2013058812A1 (en) 2011-10-19 2013-04-25 President And Fellows Of Harvard College Targeted delivery to pancreatic islet endothelial cells
EP2591801A1 (en) 2011-11-14 2013-05-15 Universitätsklinikum Hamburg-Eppendorf Nanoparticle compositions for generation of regulatory T cells and treatment of autoimmune diseases and other chronic inflammatory conditions
JP6348064B2 (ja) 2011-11-22 2018-06-27 ザ チルドレンズ ホスピタル オブ フィラデルフィア 効率の高いトランスジーン送達のためのウイルスベクター
AU2013221212B2 (en) 2012-02-17 2018-08-09 The Children's Hospital Of Philadelphia AAV vector compositions and methods for gene transfer to cells, organs and tissues
AU2013249202B2 (en) 2012-04-18 2018-08-09 The Children's Hospital Of Philadelphia Composition and methods for highly efficient gene transfer using AAV capsid variants
CA2871786C (en) 2012-04-24 2021-11-16 Ohio State Innovation Foundation Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome
BR112015005878A2 (pt) 2012-09-17 2017-07-04 Bind Therapeutics Inc nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas
CN102871966B (zh) 2012-10-19 2013-11-20 东南大学 用于改善雷帕霉素生物利用度的纳米载药颗粒及其制备方法
US9944918B2 (en) 2013-03-15 2018-04-17 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA)
US20160038575A1 (en) 2013-03-15 2016-02-11 Haplomics, Inc. Compositions and methods for immune tolerance induction to factor viii replacement therapies in subjects with hemophilia a
AU2014251099B2 (en) 2013-04-08 2019-01-17 The University Of Kansas Chimeric adeno-associated virus/ bocavirus parvovirus vector
HUE052599T2 (hu) 2013-05-03 2021-05-28 Selecta Biosciences Inc CD4+ szabályozó T-sejtek fokozására szolgáló eljárások és készítmények
IL295392A (en) 2013-06-04 2022-10-01 Selecta Biosciences Inc Repeated administration of non-immunosupressive antigen specific immunotherapeutics
JP6584012B2 (ja) 2013-10-06 2019-10-02 アメリカ合衆国 改変シュードモナス外毒素ａ
US9276815B2 (en) 2013-12-27 2016-03-01 Dell Products L.P. N-node virtual link trunking (VLT) systems management plane
EP2916319A1 (en) 2014-03-07 2015-09-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Concept for encoding of information
RS60902B1 (sr) 2014-03-09 2020-11-30 Univ Pennsylvania Kompozicije korisne u lečenju nedostatka ornitinske transkarbamilaze (otc)
GB201407322D0 (en) 2014-04-25 2014-06-11 Ospedale San Raffaele Gene therapy
US20150359865A1 (en) 2014-06-17 2015-12-17 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for t-cell-mediated autoimmune disease
US20160220501A1 (en) 2015-02-03 2016-08-04 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins
AU2015279738A1 (en) 2014-06-25 2016-12-22 Selecta Biosciences, Inc. Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
AU2015311704B2 (en) 2014-09-07 2021-12-09 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
CN107002096A (zh) 2014-10-06 2017-08-01 阿罗根有限公司 基于aav的基因疗法
CA2992262A1 (en) 2015-07-15 2017-01-19 Kyowa Hakko Kirin Co., Ltd. Antibody which specifically binds to human crth2
WO2017139212A1 (en) 2016-02-08 2017-08-17 Cyta Therapeutics, Inc. Particle delivery of rapamycin to the liver
CN108697815A (zh) 2016-02-10 2018-10-23 辉瑞公司 具有egfr配体的治疗性纳米颗粒及其制备和使用方法
ES2986077T3 (es) 2016-03-11 2024-11-08 Cartesian Therapeutics Inc Formulaciones y dosis de uricasa pegilada
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
US10545815B2 (en) 2016-08-03 2020-01-28 Futurewei Technologies, Inc. System and method for data redistribution in a database
WO2018039465A1 (en) 2016-08-25 2018-03-01 Selecta Biosciences, Inc. Polyester polymer matrices for the delivery of allergens
JP2019533718A (ja) 2016-09-27 2019-11-21 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． がんの処置における使用のための組換え免疫毒素
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
WO2018093868A1 (en) 2016-11-16 2018-05-24 University Of Florida Research Foundation, Inc. Immunoglobulin proteases, compositions, and uses thereof
EP3565605A1 (en) 2017-01-03 2019-11-13 ethris GmbH Ornithine transcarbamylase coding polyribonucleotides and formulations thereof
US20180193482A1 (en) 2017-01-07 2018-07-12 Selecta Biosciences, Inc. Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
WO2018169811A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
AU2018347583A1 (en) 2017-10-13 2020-05-21 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector IgM responses
KR102810631B1 (ko) 2018-02-26 2025-05-23 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 약물 전달 시스템
WO2019217552A1 (en) 2018-05-09 2019-11-14 Yale University Particles for spatiotemporal release of agents
US20200038463A1 (en) 2018-07-16 2020-02-06 Selecta Biosciences, Inc. Methods and compositions of mma constructs and vectors
AU2019308567A1 (en) 2018-07-16 2021-01-28 Selecta Biosciences, Inc. Methods and compositions of OTC constructs and vectors
CN114126666A (zh) 2019-04-28 2022-03-01 西莱克塔生物科技公司 用于治疗针对病毒转移载体具有预先存在的免疫力的对象的方法
CA3141863A1 (en) 2019-05-28 2020-12-03 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
CN114207440A (zh) 2019-06-04 2022-03-18 西莱克塔生物科技公司 聚乙二醇化尿酸酶的制剂和剂量
EP4048269A1 (en) 2019-10-21 2022-08-31 Selecta Biosciences, Inc. Methods and compositions for treating liver diseases and disorders
US20210187081A1 (en) 2019-11-08 2021-06-24 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
KR20220146559A (ko) 2020-02-26 2022-11-01 셀렉타 바이오사이언시즈, 인크. 면역억제제를 포함하는 합성 나노담체를 사용하는 방법 및 조성물
AU2021236234A1 (en) 2020-03-11 2022-10-06 Selecta Biosciences, Inc. Methods and compositions related to synthetic nanocarriers
CN120078887A (zh) 2020-09-21 2025-06-03 上海宝济药业股份有限公司 一种药物组合及其应用
IL302539A (en) 2020-11-04 2023-07-01 Selecta Biosciences Inc Compositions for reducing immune responses against immunoglobulin proteases
EP4274571A1 (en) 2021-01-05 2023-11-15 Selecta Biosciences, Inc. Viral vector dosing protocols
EP4319747A1 (en) 2021-04-09 2024-02-14 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
US20230140196A1 (en) 2021-10-12 2023-05-04 Selecta Biosciences, Inc. Viral vector dosing protocols
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
CN120813689A (zh) 2022-08-11 2025-10-17 笛卡尔疗法股份有限公司 与免疫球蛋白蛋白酶及其融合体相关的组合物和方法

Patent Citations (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946929A (en) 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4806621A (en) 1986-01-21 1989-02-21 Massachusetts Institute Of Technology Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
US5736372A (en) 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
US5804178A (en) 1986-11-20 1998-09-08 Massachusetts Institute Of Technology Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue
US5770417A (en) 1986-11-20 1998-06-23 Massachusetts Institute Of Technology Children's Medical Center Corporation Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo
US5019379A (en) 1987-07-31 1991-05-28 Massachusetts Institute Of Technology Unsaturated polyanhydrides
US5010167A (en) 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
US5696175A (en) 1993-01-15 1997-12-09 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
US5514378A (en) 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5578325A (en) 1993-07-23 1996-11-26 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US6123727A (en) 1995-05-01 2000-09-26 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
US5700674A (en) 1995-08-24 1997-12-23 Kikkoman Corporation Mutant uricase, a mutant uricase gene, a novel recombinant DNA, and a process for producing mutant uricase
US6095148A (en) 1995-11-03 2000-08-01 Children's Medical Center Corporation Neuronal stimulation using electrically conducting polymers
US5902599A (en) 1996-02-20 1999-05-11 Massachusetts Institute Of Technology Biodegradable polymer networks for use in orthopedic and dental applications
WO1998002441A2 (en) 1996-07-12 1998-01-22 Ariad Pharmaceuticals, Inc. Non immunosuppressive antifungal rapalogs
US5837752A (en) 1997-07-17 1998-11-17 Massachusetts Institute Of Technology Semi-interpenetrating polymer networks
US6506577B1 (en) 1998-03-19 2003-01-14 The Regents Of The University Of California Synthesis and crosslinking of catechol containing copolypeptides
US6632922B1 (en) 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6632671B2 (en) 2000-02-28 2003-10-14 Genesegues, Inc. Nanoparticle encapsulation system and method
US20080145441A1 (en) 2000-10-16 2008-06-19 Midatech Limited Nanoparticles
US6913915B2 (en) 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US6818732B2 (en) 2001-08-30 2004-11-16 The Regents Of The University Of California Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
US20090028910A1 (en) 2003-12-19 2009-01-29 University Of North Carolina At Chapel Hill Methods for Fabrication Isolated Micro-and Nano-Structures Using Soft or Imprint Lithography
US20060002852A1 (en) 2004-07-01 2006-01-05 Yale University Targeted and high density drug loaded polymeric materials
WO2009051837A2 (en) 2007-10-12 2009-04-23 Massachusetts Institute Of Technology Vaccine nanotechnology
US8455510B2 (en) 2008-09-18 2013-06-04 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Rapamycin carbonic ester analogues, pharmaceutical compositions, preparations and uses thereof
WO2014179771A1 (en) * 2013-05-03 2014-11-06 Selecta Biosciences, Inc. Dosing combinations for reducing undesired humoral immune responses
US20160128987A1 (en) 2014-11-05 2016-05-12 Selecta Biosciences, Inc. Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state
US20160128986A1 (en) 2014-11-05 2016-05-12 Selecta Biosciences, Inc. Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog

Non-Patent Citations (35)

* Cited by examiner, † Cited by third party
Title
"Concise Encyclopedia of Polymer Science and Polymeric Amines and Ammonium Salts", 1980, PERGAMON PRESS
"Handbook of Industrial Mixing: Science and Practice", 2004, JOHN WILEY & SONS, INC.
"Microcapsules and Nanoparticles in Medicine and Pharmacy", 1992, CRC PRESS
"PCR Technology. Principles and Applications for DNA Amplification", 1989, STOCKTON PRESS
"Pharmaceutics: The Science of Dosage Form Design", 2001, CHURCHILL LIVINGSTONE
"Principles of Polymerization by Odian", 2004, JOHN WILEY & SONS
ALLCOCK ET AL.: "Contemporary Polymer Chemistry", 1981, PRENTICE-HALL
BAYLE ET AL., CHEMISTRY & BIOLOGY, vol. 13, 2006, pages 99 - 107
C. ASTETE ET AL.: "Synthesis and characterization of PLGA nanoparticles", J. BIOMATER. SCI. POLYMER EDN, vol. 17, no. 3, 2006, pages 247 - 289, XP009134610
C. REIS ET AL.: "Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles", NANOMEDICINE, vol. 2, 2006, pages 8 - 21
DARIA B. CRITTENDEN ET AL: "New Therapies for Gout", ANNUAL REVIEW OF MEDICINE : SELECTED TOPICS IN THE CLINICALSCIENCES, vol. 64, no. 1, 14 January 2013 (2013-01-14), US, pages 325 - 337, XP055338466, ISSN: 0066-4219, DOI: 10.1146/annurev-med-080911-105830 *
DEMING ET AL., NATURE, vol. 390, 1997, pages 386
JOHN S. SUNDY, MD, PHD; HERBERT S. B. BARAF, MD; ROBERT A. YOOD, MD ET AL.: "Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment: Two Randomized Controlled Trials", JAMA, vol. 306, no. 7, 2011, pages 711 - 720
K. AVGOUSTAKIS: "Pegylated Poly(Lactide) and Poly(Lactide-Co-Glycolide) Nanoparticles: Preparation, Properties and Possible Applications in Drug Delivery", CURRENT DRUG DELIVERY, vol. 1, 2004, pages 321 - 333, XP009134627
LANGER, ACC. CHEM. RES., vol. 33, 2000, pages 94
LANGER, J. CONTROL. RELEASE, vol. 62, 1999, pages 7
LIM ET AL., J. AM. CHEM. SOC., vol. 123, 2001, pages 2460
LOOK ET AL.: "Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice", J. CLINICAL INVESTIGATION, vol. 123, no. 4, 2013, pages 1741 - 1749
MARK REINDERS: "New advances in the treatment of gout: review of pegloticase", THERAPEUTICS AND CLINICAL RISK MANAGEMENT, vol. Volume 6, 1 October 2010 (2010-10-01), pages 543 - 550, XP055478345, DOI: 10.2147/TCRM.S6043 *
MATHIOWITZ ET AL., J. APPL. POLYMER SCI., vol. 35, 1988, pages 755
MATHIOWITZ ET AL., J. CONTROL. RELEASE, vol. 5, 1987, pages 13
MATHIOWITZ ET AL., REACTIVE POLYMERS, vol. 6, 1987, pages 275
MICHAEL A. BECKER, M.D.; H. RALPH SCHUMACHER, JR., M.D.; ROBERT L. WORTMANN, M.D.; PATRICIA A. MACDONALD, B.S.N., N.P.; DENISE EUS: "Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout", N ENGL J MED, vol. 353, 8 December 2005 (2005-12-08), pages 2450 - 2461
MURRAY ET AL., ANN. REV. MAT. SCI., vol. 30, 2000, pages 545
P. PAOLICELLI ET AL.: "Surface-modified PLGA-based Nanoparticles that can Efficiently Associate and Deliver Virus-like Particles", NANOMEDICINE, vol. 5, no. 6, 2010, pages 843 - 853
PAPISOV, ACS SYMPOSIUM SERIES, vol. 786, 2001, pages 301
PARK ET AL., ANTICANCER RES., vol. 1, 1981, pages 373 - 376
PELLEGRINO ET AL., SMALL, vol. 1, 2005, pages 48
SAMBROOK, J ET AL.: "Molecular Cloning. A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
SCHLESINGER N, SEMIN. ARTHRITIS RHEUM., vol. 42, no. 2, 1 October 2012 (2012-10-01), pages 155 - 65
SUNDY ET AL.: "Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout", ARTHRITIS AND RHEUMATISM, vol. 56, no. 3, March 2007 (2007-03-01), pages 1021 - 1028, XP055081047, DOI: doi:10.1002/art.22403
TAKASHI K. KISHIMOTO ET AL: "Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles", NATURE NANOTECHNOLOGY, vol. 11, no. 10, 1 August 2016 (2016-08-01), GB, pages 890 - 899, XP055371105, ISSN: 1748-3387, DOI: 10.1038/nnano.2016.135 *
UHRICH ET AL., CHEM. REV., vol. 99, 1999, pages 3181
WANG ET AL., J. AM. CHEM. SOC., vol. 123, 2001, pages 9480
ZAPLIPSKY; LEE: "Polyethylene Glycol Chemistry: Biotechnical and Biomedical Applications", 1992, PLENUM PRESS

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11717569B2 (en) 2011-04-29 2023-08-08 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers
US11235057B2 (en) 2011-04-29 2022-02-01 Selecta Biosciences, Inc. Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses
US11779641B2 (en) 2011-04-29 2023-10-10 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for allergy therapy
US11298342B2 (en) 2013-05-03 2022-04-12 Selecta Biosciences, Inc. Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity
US12508249B2 (en) 2013-05-03 2025-12-30 Cartesian Therapeutics Inc. Methods related to administering immunosuppressants and non-allergenic antigens to reduce or prevent anaphylaxis
US12472167B2 (en) 2013-05-03 2025-11-18 Cartesian Therapeutics, Inc. Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both Type 1 and Type IV hypersensitivity
US11633422B2 (en) 2014-09-07 2023-04-25 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector immune responses
US12194078B2 (en) 2017-03-11 2025-01-14 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
US11426451B2 (en) 2017-03-11 2022-08-30 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with antiinflammatories and synthetic nanocarriers comprising an immunosuppressant
US12553041B2 (en) 2019-06-04 2026-02-17 Cartesian Therapeutics Inc. Formulations and doses of pegylated uricase
KR102260478B1 (ko) 2019-08-19 2021-06-02 연세대학교 산학협력단 일나트륨 요소화물 결정 용해용 조성물
KR20210021882A (ko) * 2019-08-19 2021-03-02 연세대학교 산학협력단 통풍 치료용 약학적 조성물 및 통풍 치료용 키트
WO2021081062A1 (en) * 2019-10-21 2021-04-29 Selecta Biosciences, Inc. Methods and compositions for treating liver diseases and disorders
CN115038441A (zh) * 2019-10-21 2022-09-09 西莱克塔生物科技公司 用于治疗肝疾病和病症的方法和组合物
WO2021092354A1 (en) * 2019-11-08 2021-05-14 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
JP2023501457A (ja) * 2019-11-08 2023-01-18 セレクタ バイオサイエンシーズ インコーポレーテッド ペグ化ウリカーゼの処方物および用量
JP7821105B2 (ja) 2019-11-08 2026-02-26 セレクタ バイオサイエンシーズ インコーポレーテッド ペグ化ウリカーゼの処方物および用量
WO2022098901A1 (en) * 2020-11-04 2022-05-12 Selecta Biosciences, Inc. Compositions for reducing immune responses against immunoglobulin proteases
US20220133864A1 (en) * 2020-11-04 2022-05-05 Selecta Biosciences, Inc. Methods and compositions for reducing immune responses against immunoglobulin proteases

Also Published As

Publication number Publication date
BR112019018748A2 (pt) 2020-04-07
US20180289776A1 (en) 2018-10-11
ES3036482T3 (en) 2025-09-19
IL269200A (en) 2019-11-28
US20230107561A1 (en) 2023-04-06
US11426451B2 (en) 2022-08-30
JP2020510687A (ja) 2020-04-09
KR20190124295A (ko) 2019-11-04
US20250108094A1 (en) 2025-04-03
US20230119226A1 (en) 2023-04-20
EP4599848A3 (en) 2025-12-03
EP3592389B1 (en) 2025-05-07
EP4599848A2 (en) 2025-08-13
HUE072005T2 (hu) 2025-10-28
CA3055936A1 (en) 2018-09-20
AU2018236123B2 (en) 2024-04-18
CN110612122A (zh) 2019-12-24
JP7523909B2 (ja) 2024-07-29
JP2024083324A (ja) 2024-06-20
US12194078B2 (en) 2025-01-14
AU2018236123A1 (en) 2019-10-03
EP3592389A1 (en) 2020-01-15
AU2024204850A1 (en) 2024-08-01
KR20250011715A (ko) 2025-01-21
KR102753928B1 (ko) 2025-01-14
MX2019010757A (es) 2020-01-20
EP3592389C0 (en) 2025-05-07

Similar Documents

Publication Publication Date Title
US12194078B2 (en) Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
US20250057756A1 (en) Formulations and doses of pegylated uricase
US12553041B2 (en) Formulations and doses of pegylated uricase
AU2020380944A1 (en) Formulations and doses of pegylated uricase
RU2831122C2 (ru) Композиции и дозы пегилированной уриказы
BR112019018748B1 (pt) Composições e seus usos no tratamento combinado com antiinflamatórios e nanocarreadores sintéticos compreendendo um imunossupressor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18714906

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3055936

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 122022026000

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2019549532

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019018748

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2018236123

Country of ref document: AU

Date of ref document: 20180311

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20197029716

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018714906

Country of ref document: EP

Effective date: 20191011

ENP Entry into the national phase

Ref document number: 112019018748

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190910

WWG Wipo information: grant in national office

Ref document number: MX/A/2019/010757

Country of ref document: MX

WWG Wipo information: grant in national office

Ref document number: 2018714906

Country of ref document: EP